Topical cosmetic neurotransmitter-inhibiting peptide

SNAP-8

A topical acetyl octapeptide studied in cosmetic science as a SNAP-25–related expression-line research ingredient.

Also referred to as: acetyl octapeptide-3, acetyl glutamyl heptapeptide-3, SNAP-8 peptide
Research use only. This page summarizes published scientific literature. It is not medical advice, not a recommendation, and not a claim that this compound treats, cures or prevents any condition. Nothing here is a suggestion to use it.

What SNAP-8 is

SNAP-8 (acetyl octapeptide-3) is an eight-amino-acid cosmetic peptide elongated from the acetyl hexapeptide-8 (Argireline) scaffold. It is investigated as a topical modulator of SNARE-complex machinery involved in catecholamine release at neuromuscular junctions of facial expression muscles.

Evidence is strongest in cosmetic-ingredient and delivery-system literature rather than large independent drug trials. Manufacturer-linked clinical cosmetology work and later microneedle-patch studies examine wrinkle-depth and skin-quality endpoints after repeated topical application of dilute peptide solutions.

SNAP-8 is not an injectable research peptide in the GH-secretagogue sense. Dosage education should emphasize percent strength of cosmetic solutions and topical frequency, not subcutaneous mcg charts.

How it works

SNAP-8 is designed to interfere with SNAP-25 participation in SNARE complex assembly, reducing vesicle-fusion efficiency for acetylcholine release in a milder, topical paradigm compared with botulinum toxin cleavage of SNAP-25. Less neurotransmitter release at expression-muscle junctions is the proposed path to softer dynamic lines. As a topical oligopeptide, penetration and vehicle design strongly influence observed activity.

Who works with it, and what they are measuring

Cosmetic chemists, dermatocosmetic clinical units, and transdermal delivery engineers are the main research users. Injectables-focused peptide labs sometimes analyze it only as a comparator or analytical target in multi-peptide skincare products.

What the research examines

cosmetic peptide formulationexpression-line / wrinkle cosmetologySNARE complex modulationmicroneedle and patch delivery systemscomparative studies vs acetyl hexapeptide-8

Each tag marks a field where this compound appears in research. Appearing in a literature is not the same as working.

How it appears in the literature

Figures as they appear in the source literature. Context matters more than the number.

Research contextReported amountFrequencyRoute
Cosmetic solution use levels in finished formulas (manufacturer-linked clinical cosmetology)3 mcg – 10 mcgtwice daily topicaltopical
Microneedle patch clinical cosmetology studies including acetyl octapeptide-31 mcg – 100 mcgper patch protocoltopical / microneedle-assisted dermal delivery
See the full SNAP-8 dosage chart, reconstitution math and calculator →

Handling & storage

Finished SNAP-8 solutions and serums are typically stored cool and away from light; avoid high-heat compounding steps after peptide addition. Lyophilized raw peptide, when used by formulators, is kept dry and cold until incorporated into a validated vehicle.

Notes on combined research

Cosmetic research frequently combines SNAP-8 with acetyl hexapeptide-8, moisturizing polymers, antioxidants, or hyaluronic acid delivery systems. The goal is complementary barrier, hydration, and expression-line pathways in a topical chassis. This is formulation stacking, not an injectable peptide stack.

SNAP-8 questions

Cosmetic research and supplier guidance commonly use about 3–10% of a commercial SNAP-8 peptide solution in the final topical formula, applied once or twice daily in study designs. That is a formulation percentage, not a subcutaneous mcg dose.

If starting from lyophilized raw peptide, formulators use validated aqueous vehicles, not necessarily bacteriostatic water meant for multi-dose injections. Many users never recon a vial at all because they buy a pre-made cosmetic solution.

Topical studies often apply the finished product twice daily to expression-line areas. There is no standard daily injectable schedule in legitimate SNAP-8 literature.

Useful charts list percent solution in emulsion/serum, application frequency, and study duration (for example 28 days). Injectables-style mcg charts misrepresent the compound class.

Systemic half-life is the wrong primary metric. Interest centers on local cutaneous activity and formula stability rather than plasma PK.

Yes in formulation research: it is often paired with Argireline-class peptides, hydrators, and delivery enhancers. Injectable stacking is not the evidence-based use case.

No. It is a topical cosmetic peptide investigated as a milder SNARE-pathway approach. It is not a botulinum toxin injection substitute in medical practice.

SNAP-8 is an elongated analogue of acetyl hexapeptide-8 (Argireline). Supplier comparisons claim incremental wrinkle-score improvements; independent effect sizes vary by vehicle and study quality.

Read the research yourself

Each citation was checked against PubMed before it went on this page. If we cannot link it, we do not claim it.

Reference information only. The values below summarize amounts reported in published research literature and laboratory protocol discussions. They are not dosing recommendations, not medical advice, and not instructions for use in humans. All compounds referenced are for laboratory research use only and are not for human consumption.